Pneumagen has announced the initiation of a Phase 1 SAD/MAD study of its Neumifil carbohydrate binding module (mCBM) nasal spray, which the company is developing for the prevention and treatment of viral respiratory infections. The company said that it expects topline results to be available in the first half of 2022.
At the beginning of 2021, Pneumagen announced that it had raised £2.5 million for clinical development of Neumifil and in March 2021, the company presented data from preclinical studies demonstrating the potential of Neumifil against COVID-19.
Pneumagen CEO Douglas Thomson said, “The start of this Phase 1 study is a major milestone for Pneumagen, and we are very pleased that we have made the step to become a clinical stage biotech company. We are extremely excited by the prospect of developing Neumifil as both a prophylactic and treatment for multiple viral respiratory tract infections, including influenza and COVID-19. As an easy-to-use nasal spray that could be prescribed to those at risk of viral exacerbations, Neumifil has the potential to prevent more serious disease, hospitalization and the need for critical care for patients. Neumifil is being developed as a safe, effective and convenient to self-administer option with the potential to transform the treatment of viral pandemics and infectious diseases.”
Read the Pneumagen press release.
